Concord Drugs

What Concord Drugs does

Concord Drugs Limited is a Hyderabad-based pharmaceutical contract manufacturer incorporated in 1995 and publicly listed on the Ahmedabad, Pune, and Madras Stock Exchanges. The company operates a WHO-GMP certified Formulation-Fill-Finish facility spanning 7 acres with 2,00,000 square feet of built-up area at Brahmanapally Village, supplemented by a second manufacturing unit in Roorkee, Uttarakhand established in 2005 for tablets and capsules. Its product portfolio spans ready-to-fill pellets and MUPS (Multiple Unit Pellet System), oral solid dosages (tablets and capsules) manufactured in separate Betalactam and non-Betalactam facilities, injectables including small volume parenterals and dry powders, liquid orals (syrups and suspensions), and dry syrups with 25,000-bottle-per-shift capacity. The underlying technology centers on advanced drug-delivery platforms enabling immediate, sustained, extended, and delayed release formulations.

The company derives revenue primarily through B2B contract manufacturing for domestic and international pharmaceutical companies, with a disclosed client base of over thirty leading Indian pharma firms including Crescent Therapeutics, Veritaz Healthcare, Cian Healthcare, Medichem Pharma, Sunlife Sciences, and Srinivasa Medical Agencies. Its proprietary AMCRYLATE tissue bio-adhesive (ISO Amyl 2-Cyanoacrylate), developed with IICT Hyderabad and mass-produced with TIFAC's support, holds an India patent and CE certification, representing a differentiated branded offering sold alongside the contract manufacturing base. PROTON SAFE hand sanitizers are additionally manufactured on a third-party basis.

For the fiscal year ending March 2026, Concord reported sales of Rs 78.74 crore, a 74.05% year-over-year increase, with Q4 FY2026 sales of Rs 37.89 crore (up 264.68%) and full-year net profit of Rs 1.06 crore. The company operates a sales-led, direct-relationship go-to-market without public pricing disclosure, and is family-controlled, with the Nagi Reddy family occupying the Managing Director, Whole-time Director, and CFO positions, supplemented by independent directors and a Company Secretary.

Name

Concord Drugs

Legal name

Concord Drugs Limited

Website

https://concorddrugs.in

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Concord Drugs Limited is a Hyderabad-based pharmaceutical contract manufacturer producing ready-to-fill pellets, MUPS, tablets, capsules, injectables, liquid orals, dry syrups, and the patented AMCRYLATE tissue bio-adhesive for B2B pharma clients across India.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract pharmaceutical manufacturing
• Ready-to-fill pellets
• MUPS technology
• Pharmaceutical formulations
• Tissue bio-adhesive

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Pharmaceutical Manufacturing: The company operates as a contract manufacturer for pharmaceutical formulations. Concord Drugs provides end-to-end solutions including Ready-to-fill Pellets and Finished Pharmaceutical Formulations for customers and partners. Manufacturing services cover tablets, capsules, injectables, liquid orals, dry syrups, and pellets.
2. Product Sales - AMCRYLATE: Sale of proprietary tissue bio-adhesive product AMCRYLATE which is patented in India. The product is manufactured and marketed for sutureless surgeries.
3. Third Party Manufacturing - Hand Sanitizers: Manufacturing of hand sanitizers (Brand: PROTON SAFE) on third party basis for other companies across India.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Concord Drugs Limited is a pharmaceutical contract manufacturer offering end-to-end formulation development and commercial-scale production of finished dosage forms. The company manufactures ready-to-fill pellets, MUPS, tablets, capsules, injectables, liquid orals, dry syrups, and the proprietary Amcrylate tissue bio-adhesive for third-party pharmaceutical clients. Operations are conducted from WHO-GMP certified facilities serving other pharmaceutical marketers, brand owners, and formulators requiring outsourced manufacturing capacity.

Product overview

Concord Drugs Limited operates as a contract pharmaceutical manufacturer offering a diversified portfolio of finished pharmaceutical formulations and semi-finished products. The core product portfolio includes Ready-to-Fill Pellets & MUPS (for extended/delayed release technologies), Tablets, Capsules, Injectables (Small Volume Parenterals and Dry Powders), Liquid Orals (Syrups & Suspensions), and Dry Syrups. The company also manufactures Amcrylate, a patented Tissue Bio-Adhesive for sutureless surgeries developed in collaboration with IICT Hyderabad. Additional products include PROTON SAFE hand sanitizers. The company provides end-to-end pharmaceutical development and manufacturing services with WHO-GMP certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

• AMCRYLATE: Tissue Bio-Adhesive (ISO Amyl 2-Cyanoacrylate) - a sterile tissue adhesive used in sutureless surgeries. First time in Asia, developed in collaboration with Indian Institute of Chemical Technology (IICT), Hyderabad. Patented in India.
• PROTON SAFE

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Indian Institute of Chemical Technology (IICT), HyderabadcoreStrategic or Co-development PartnerCollaboration with premier CSIR laboratory for development of AMCRYLATE tissue bio-adhesive product. IICT provided technological expertise for first-time development of sterile tissue adhesive in Asia.
• Technology Information, Forecasting and Assessment Council (TIFAC), New DelhicoreStrategic or Co-development PartnerTIFAC helped mass produce AMCRYLATE and bring it to Indian consumers. Provided techno-managerial guidance to the company.

Scale indicators5 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Hikal Limited: Indian CDMO offering APIs, intermediates, and contract manufacturing services to pharma and agrochemical customers. Comparable mid-scale contract manufacturing business model targeting innovator and generic customers.
• Neuland Laboratories: India-listed API and intermediates CDMO of similar mid-cap scale to Concord. Closely comparable on contract manufacturing focus, smaller scale relative to top-tier CDMOs, and India-based operations targeting regulated markets.
• Granules India: Indian-listed pharma manufacturer focused on finished dosages, API, and PFIs, with significant contract manufacturing revenue. Closely comparable formulation CDMO model serving global generics customers.
• SMS Pharmaceuticals: India-listed API and formulation manufacturer of similar mid-cap scale. Provides contract manufacturing for generic APIs and finished formulations — directly comparable in size and business model to Concord.
• Suven Pharmaceuticals: Indian CDMO focused on niche APIs and custom synthesis for global pharma. Similar in size and business model to Concord, providing outsourced development and manufacturing services to innovator and generic drug companies.

Broad incumbents

• Piramal Pharma Solutions: Global CDMO arm of Piramal Pharma offering integrated drug substance and drug product services. Directly comparable contract manufacturing business to Concord, especially in solid oral dosage forms and injectables, but with global scale.
• Aurobindo Pharma: Large Indian generics manufacturer with substantial contract manufacturing and formulation export operations. Competes with Concord for domestic and export formulation contracts.
• Divi's Laboratories: One of India's largest API and intermediates CDMOs. Comparable to Concord's API/intermediates and contract manufacturing orientation, but operates globally with USFDA-inspected facilities and substantially larger capacity.
• Laurus Labs: Indian-listed CDMO with strengths in APIs, formulation, and synthesis. Competes with Concord for contract manufacturing work targeting regulated generics and innovator APIs.
• Syngene International: India-listed CRO/CDMO offering contract manufacturing and research services to global pharma. Like Concord, it serves as an outsourced manufacturing partner, but at vastly greater scale and with broader biologics/small-molecule capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concord Drugs